/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

SOL-GEL TECHNOLOGIES LTD share price today is $85.2, up -9.52%. The stock opened at $85.26 against the previous close of $94.29, with an intraday high of $85.7 and low of $83.54.

style

pb-0

SOL-GEL TECHNOLOGIES LTD

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$85.2 -0.0952(-9.52%) SLGL at 13 Mar 2026 03:15 PM Biotechnology

Lowest Today 83.54

Highest Today 85.7

Today’s Open 85.26

Prev. Close 94.29

52 Week High 97.97

52 Week Low 4.02

Day’s Range: Low 83.54 High 85.7

52-Week Range: Low 4.02 High 97.97

SOL-GEL TECHNOLOGIES LTD Institutional Holdings

SOL-GEL TECHNOLOGIES LTD Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

SOL-GEL TECHNOLOGIES LTD Fundamentals

Market Cap 99.10 M

PB Ratio 10.0911

PE Ratio 0.0

Enterprise Value 242.91 M

Total Assets 35.85 M

Volume 42288

SOL-GEL TECHNOLOGIES LTD Company Financials

Annual Revenue FY23:1207000 1.2M, FY22:3883000 3.9M, FY21:31272000 31.3M, FY20:8771000 8.8M, FY19:22904000 22.9M

Annual Profit FY23:null 0.0M, FY22:3883000 3.9M, FY21:31272000 31.3M, FY20:8771000 8.8M, FY19:22904000 22.9M

Annual Net worth FY23:-28187000 -28.2M, FY22:-13602000 -13.6M, FY21:4358000 4.4M, FY20:-27401000 -27.4M, FY19:-24609000 -24.6M

Quarterly Revenue Q3/2025:400000 0.4M, Q2/2025:17261000 17.3M, Q1/2025:1031000 1.0M, Q3/2024:5361000 5.4M, Q2/2024:5433000 5.4M

Quarterly Profit Q3/2025:400000 0.4M, Q2/2025:17261000 17.3M, Q1/2025:1031000 1.0M, Q3/2024:5361000 5.4M, Q2/2024:2995000 3.0M

Quarterly Net worth Q3/2025:-5942000 -5.9M, Q2/2025:11610000 11.6M, Q1/2025:-8808000 -8.8M, Q3/2024:-366000 -0.4M, Q2/2024:1976000 2.0M

About SOL-GEL TECHNOLOGIES LTD & investment objective

Company Information Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Organisation Biotechnology

Employees 34

Industry Biotechnology

CEO Mr. Moshe Arkin

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*